Jianmin Pharmaceutical Group Co.,Ltd. (SH: 600976) has announced that it has received the Drug Registration Certificate from China's National Medical Products Administration. This approval clears the way for the company's newly developed crisaborole ointment to enter the market.
The ointment is indicated for topical treatment in patients aged three months and older who suffer from mild to moderate atopic dermatitis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.